Skip to main content
GutCited

N-Acetyl Cysteine (NAC) Inflammatory Bowel Disease (IBD) — General

D

Pilot data only. Glutathione precursor may reduce oxidative stress in IBD. Requires larger clinical trials.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dn\u002Dacetyl\u002Dcysteine\u0026condition\u003Dinflammatory\u002Dbowel\u002Ddisease'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

D

結論

Pilot data only. Glutathione precursor may reduce oxidative stress in IBD. Requires larger clinical trials.

Key Study Findings

Review
Nanocatalytic Antioxidation: A General Chemical Approach for Alleviating Oxidative Stress in Diseases.
Dose: None vs: None Outcome: None 効果: None None

対象集団: Review of nanocatalytic antioxidation in diseases

Randomized Controlled Trial 16 weeks Open-label
Exploring the role of oxidative stress and the effect of N-acetylcysteine in thiopurine-induced liver injury …
Dose: N-acetylcysteine with thiopurine vs: Thiopurine alone (crossover) Outcome: Liver injury markers and oxidative stress 効果: None None

対象集団: IBD patients with thiopurine-induced liver injury

Review
The emerging role of oxidative stress in inflammatory bowel disease.
Dose: None vs: None Outcome: Oxidative stress role in IBD pathophysiology 効果: None None

対象集団: IBD patients (Crohn's and UC)

In Vitro 4.3 weeks
Extraintestinal Manifestations in Induced Colitis: Controversial Effects of N-Acetylcysteine on Colon, Liver, and Kidney.
Dose: 150 mg/kg vs: None Outcome: inflammation markers 効果: None None

対象集団: Mice

Systematic Review 52 weeks
Vitamin D for the treatment of inflammatory bowel disease.
Dose: 400 IU/day vs: placebo Outcome: IBD disease activity 効果: None None

対象集団: Patients with IBD

Review
Role of ferroptosis in the pathogenesis and as a therapeutic target of inflammatory bowel disease …
Dose: None vs: None Outcome: Ferroptosis role in IBD pathogenesis 効果: None None

対象集団: IBD patients (mechanistic review)

Key Statistics

1

研究数

30

参加者数

Positive

D

グレード

Referenced Papers

Frontiers in endocrinology 2024 165 件の引用
Pharmaceuticals (Basel, Switzerland) 2023 18 件の引用
The Cochrane database … 2023 1 件の引用
European journal of … 2021 40 件の引用
The British journal … 2012 145 件の引用

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

一般的な使用量

general:
600-1,200 mg/day in divided doses
hpyloriadjunct:
600 mg twice daily alongside standard triple therapy
antioxidantsupport:
600-900 mg/day

上限量: Generally well-tolerated up to 1,800 mg/day; higher doses used in clinical settings

研究で検討された用量

用量 期間 効果 N
None -- Mixed --
N-acetylcysteine with thiopurine 16 weeks Positive --
None -- Positive --
150 mg/kg 4.3 weeks Positive --
400 IU/day 52 weeks Mixed --
None -- Neutral --
Various antioxidant compounds -- Positive --
None -- Mixed --

推奨摂取タイミング: With or without food; divide doses throughout the day

Safety & Side Effects

報告されている副作用

  • Nausea and vomiting (most common, especially at higher doses)
  • Diarrhea
  • Unpleasant sulfur taste/odor
  • Headache

既知の相互作用

  • Nitroglycerin (NAC may enhance vasodilatory effects; risk of hypotension)
  • Activated charcoal (may reduce NAC absorption)
  • Anticoagulants (NAC may have mild antiplatelet effects)
  • ACE inhibitors (additive hypotensive effect with nitroglycerin combination)

耐容上限摂取量: Generally well-tolerated up to 1,800 mg/day; higher doses used in clinical settings

サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。

Frequently Asked Questions

Does N-Acetyl Cysteine (NAC) help with Inflammatory Bowel Disease (IBD) — General?
Based on 1 studies with 30 participants, there is preliminary evidence that needs more research that N-Acetyl Cysteine (NAC) may support Inflammatory Bowel Disease (IBD) — General management. Our evidence grade is D (Very Early Research).
How much N-Acetyl Cysteine (NAC) should I take for Inflammatory Bowel Disease (IBD) — General?
Studies have used various dosages. A commonly studied range is 600-1,200 mg/day in divided doses. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of N-Acetyl Cysteine (NAC)?
Reported side effects may include Nausea and vomiting (most common, especially at higher doses), Diarrhea, Unpleasant sulfur taste/odor, Headache. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for N-Acetyl Cysteine (NAC) and Inflammatory Bowel Disease (IBD) — General?
We rate the evidence as Grade D (Very Early Research). This rating is based on 1 peer-reviewed studies with 30 total participants. The overall direction of effect is positive.

Related Evidence

に関する他の成分: Inflammatory Bowel Disease (IBD) — General

N-Acetyl Cysteine (NAC) 他の症状・状態について

FDAに関する免責事項: これらの記述は米国食品医薬品局(FDA)による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。